¡ÚǾ¤Ï¹³»À²½Êª¼Á¤Ç¼é¤é¤ì¤Æ¤¤¤ë¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㤽¤Î¾¡ä

0

    JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

     

    ¡ÚǾ¤Ï¹³»À²½Êª¼Á¤Ë¤è¤Ã¤Æ¼é¤é¤ì¤Æ¤¤¤ë¡Û

     

    ­¡¥°¥ë¥¿¥Á¥ª¥ó¡ÊGSH¡Ë
    ­¢¥á¥¿¥í¥Á¥ª¥Í¥¤¥ó
    ­£¥»¥ì¥ó
    ­¤¥¹¡¼¥Ñ¡¼¥ª¥­¥·¥É¡¦¥Ç¥£¥¹¥à¥¿¡¼¥¼¡ÊSOD¡Ë
    ­¥¥«¥¿¥é¡¼¥¼
    ­¦¥Ó¥¿¥ß¥óC
    ­§¥·¥¹¥Æ¥¤¥ó

     

    ¢¨¥°¥ë¥¿¥Á¥ª¥ó¤ÎÀ¸ÍýŪµ¡Ç½¤Ï¿¡¹¤¢¤ê¤Þ¤¹¤¬¡¢¼çÍפʵ¡Ç½¤ÏÂ礭¤¯2¤Ä¤Ëʬ¤±¤ë¤³¤È¤¬¤Ç¤­¤Þ¤¹¡£

    ¤Ò¤È¤Ä¤ÏºÙ˦Æâ¤Î¥Á¥ª¡¼¥ë´Ä¶­¤ò°Ý»ý¤¹¤ë¤³¤È¤Ç¤¹¡£¥Á¥ª¡¼¥ë¤ÏÀ¸ÂÎÆâ¤Î¼çÍפʹ³»À²½À®Ê¬¡£¥°¥ë¥¿¥Á¥ª¥ó¤Ï¼«¤é¤Î¥Á¥ª¡¼¥ë´ð¤òÍѤ¤¤Æ²á»À²½Êª¤ä³èÀ­»ÀÁǼï¤ò´Ô¸µ¤·¤Æ¾Ãµî¤¹¤ë¡£¤Þ¤¿¡¢¥¿¥ó¥Ñ¥¯¼ÁÃæ¤Î¥¸¥¹¥ë¥Õ¥£¥É·ë¹ç¤ò´Ô¸µ¤·¤Æ2¤Ä¤Î¥Á¥ª¡¼¥ë´ð¤ËÌ᤹¡£¹¹¤Ë¡¢¥°¥ë¥¿¥Á¥ª¥ó¤ÏºÙ˦¤Î¥·¥¹¥Æ¥¤¥ó¸»¤Ç¤â¤¢¤ê¡¢¥·¥¹¥Æ¥¤¥ó¤Ï¥Á¥ª¡¼¥ë´ð¤ò´Þ¤à¡£

    ¤â¤¦¤Ò¤È¤Ä¤Î¼çÍפÊÀ¸Íýµ¡Ç½¤Ï¡¢ÍÍ¡¹¤ÊÆÇʪ¡¦Ìôʪ¡¦ÅÁãʪ¼ÁÅù¤òºÙ˦³°¤ËÇӽФ¹¤ë¤³¤È¤Ç¤¹¡£¥°¥ë¥¿¥Á¥ª¥ó¤Ï¤³¤ì¤é¤Îʪ¼Á¤ò¡¢¤ä¤Ï¤ê¥·¥¹¥Æ¥¤¥ó»Ä´ð¤Î¥Á¥ª¡¼¥ë´ð¤Ë·ë¹ç¤µ¤»¡Ê¥°¥ë¥¿¥Á¥ª¥óÊú¹ç¡Ë¡¢¼«¤éºÙ˦³°¤ËÇӽФµ¤ì¤ë¤³¤È¤Ç¡¢ºÙ˦¤ò²òÆǤ¹¤ë¡£

    ¢¨¥á¥¿¥í¥Á¥ª¥Í¥¤¥ó (metallothionein) ¤Ï¡¢1957ǯ¤ËMargoshes¤ÈVallee¤Ë¤è¤Ã¤Æ¥¦¥Þ¤Î¿Õ¡¤«¤é¥«¥É¥ß¥¦¥à¤ò·ë¹ç¤¹¤ë¥¿¥ó¥Ñ¥¯¼Á¤È¤·¤Æȯ¸«¤µ¤ì¤¿¡¢¶â°·ë¹çÀ­¤Î¥¿¥ó¥Ñ¥¯¼Á¤Ç¤¹¡£¥á¥¿¥í¥Á¥ª¥Í¥¤¥ó¤ÎÀ¸ÍýŪ¤ÊÌò³ä¤Ë¤Ä¤¤¤Æ¤Ï¿ô¿¤¯¤ÎÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢ÂåɽŪ¤Ë¤Ï¡¢­¡É¬¿ÜÈùÎ̸µÁǤι±¾ïÀ­°Ý»ý¡¢¤¢¤ë¤¤¤Ï²á¾ê¤Ê½Å¶â°¤Î²òÆÇ¡¢­¢³èÀ­»ÀÁǼï¤Ê¤É¤Î¥é¥¸¥«¥ë¤ä¥¢¥ë¥­¥ë²½ºÞ¤Î¾Ãµî¤Ç¤¹¡£

     

     


    ¡ÚEPA¤ÈDHA¤Î·ìÃæÇ»ÅÙ¤ÎÊѲ½¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㤽¤Î¾¡ä

    0

      JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

       

      ¡ÚEPA¤ÈDHA¤Î·ìÃæÇ»ÅÙ¤ÎÊѲ½¡Û


      µûÌý¡ÊEPA2100mg¡ÜDHA1100mg/Æü¡Ë¤ò4½µ´ÖÅêÍ¿¤·¤¿¸å¡¢ÅêÍ¿¤òÃæ»ß¤·¡¢8½µ´Ö²¿¤âÅêÍ¿¤·¤Ê¤«¤Ã¤¿¾ì¹ç¤ÎEPA¡¦DHAÁÈÀ®¤ò¸¡Æ¤¤·¤¿·ë²Ì¡£
      µûÌýÅêÍ¿³«»Ï¤Ëȼ¤Ã¤Æ¡¢Á´·ìÃæEPA¤Ï¤¹¤Ð¤ä¤¯¾å¾º¤·¤Þ¤·¤¿¤¬¡¢DHA¤Ï¤æ¤ë¤ä¤«¤Ê¾å¾º¤Ë¤È¤É¤Þ¤Ã¤Æ¤¤¤Þ¤¹¡£
      ¤Þ¤¿4½µ¸å¡¢µûÌýÅêÍ¿Ãæ»ß¤È¤È¤â¤ËEPA´ÞÎ̤ϵ޷ã¤ËÄã²¼¤·¤Þ¤·¤¿¤¬¡¢DHA´ÞÎ̤ϵ޷ã¤ÊÄã²¼¤Ïǧ¤á¤é¤ì¤Þ¤»¤ó¤Ç¤·¤¿¡£
      ºÇ¶á¤Î¸¦µæ¤Ë¤è¤ë¤È¡¢EPA¤Ï¡¢Ç»ÅÙ¤ò°Ý»ý¤¹¤ë¤¿¤á¤ËÀ䤨¤ºÊä½¼¤¹¤ëɬÍפ¬¤¢¤ë¤È¸À¤ï¤ì¤Æ¤¤¤Þ¤¹¡£
      °ìÊý¡¢DHA¤Ï¡¢¡Ö¹½Â¤Åª¡×¤Ê»éËûÀ¤È¤·¤Æ¤¹¤Ç¤Ë½½Ê¬ÎÌÃßÀѤ¬¤¹¤¹¤ó¤Ç¤ª¤ê¡¢EPA¤ËÈæ¤Ù¡Ö¹³±ê¾É¡×Åù¤Ë¤è¤ë¾ÃÈñ¤â¾¯¤Ê¤¤¤Î¤«¤â¤·¤ì¤Þ¤»¤ó¡£

       


      ¡Ú¥¦¥ë¥È¥éDHA¡ÊuDHA¡Ë¤È¤Ï¡©¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㤽¤Î¾¡ä

      0

        JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

         

        ¡Ú¥¦¥ë¥È¥éDHA¡ÊuDHA¡Ë¤È¤Ï¡©¡Û


        ¥Þ¥°¥í¤«¤éÃê½Ð¤·¤¿µûÌý¤ò¹ÚÁǽèÍý¤µ¤ì¡¢DHA¤Ï¥È¥ê¥°¥ê¥»¥ê¥É¤Ë¤ª¤±¤ëSn-£²°Ì¤Ë·ë¹ç¤·¤Æ¤¤¤Þ¤¹¡£
        Ä̾ï¤ÎDHA¤è¤êÀ¸ÂÎËì¤Ø¤Î¼è¤ê¹þ¤ß¤¬¹â¤¯¡¢À¸ÂÎÍøÍѸúΨ¤¬Îɤ¤¤Î¤¬ÆÃħ¤Ç¤¹¡£
        ¥Õ¥§¥ë¥é»À¤È¥Þ¥ê¡¼¥´¡¼¥ë¥É¤¬Ç۹礵¤ì¤Æ¤¤¤Þ¤¹¡£

         

        ¢ã¥Õ¥§¥ë¥é»À¢ä

        ¼ç¤ËǧÃξɤËÂФ·¤Æ»È¤ï¤ì¤Æ¤ª¤ê¡¢¹³»À²½ºîÍѤòÍ­¤·¤Æ¤¤¤Þ¤¹¡£

         

        ¢ã¥Þ¥ê¡¼¥´¡¼¥ë¥É¢ä
        ¥ë¥Æ¥¤¥ó¤ò¿¤¯´Þ¤àÅ·Á³Êª¼Á¤Ç¤¹¡£¥­¥¯²Ê¿¢Êª¥Þ¥ê¡¼¥´¡¼¥ë¥É¤Î²Ö¤Ó¤é¤«¤éÃê½Ð¤µ¤ì¤ë¥Ø¥ì¥Ë¥¨¥ó¤ÏÌÀ°Å½ç±þ²þÁ±ºîÍѤò»ý¤Á¤Þ¤¹¡£
        ÌÖË쿧ÁÇÊÑÀ­¾É¤Ï¡¢ÌܤÎÌÖËì¤Î¤Ï¤¿¤é¤­¤¬°­¤¯¤Ê¤ëɵ¤¤Ç¤¹¡£
        °Å¤¬¤ê¤Çʪ¤¬¸«¤¨¤Ë¤¯¤¯¤Ê¤Ã¤¿¤ê¡¢¸«¤¨¤ëÈϰϤ¬¶¹¤¯¤Ê¤Ã¤¿¤ê¤·¤Þ¤¹¡£
        ÌܤÎÌÖËì¤ÎÂå¼Õ¤òÂ¥¿Ê¤¹¤ë¤³¤È¤Ç¡¢ÌëÌվɾõ¤ä»ëÌºõ¤ò°ì»þŪ¤Ë²þÁ±¤·¤Þ¤¹¡£ÌÖË쿧ÁÇÊÑÀ­¾É¤Ë¤ª¤±¤ë°ì»þŪ¤Ê»ëÌ°Å½ç±þ¤Î²þÁ±Ìô¤È¤·¤Æ¥Ø¥ì¥Ë¥¨¥ó¤òÍ­¸úÀ®Ê¬¤È¤·¤¿½èÊýÌô¤È¤·¤Æ¡Ø¥¢¥À¥×¥Á¥Î¡¼¥ë¾û¡Ù¤¬¤¢¤ê¤Þ¤¹¡£

         

        ¢ãDHA¢ä
        ºÙ˦Ëì¤ÏήưÀ­¤ò»ý¤Á¡¢Î®Æ°À­¤ÏËì¤Î¹½À®Êª¼Á¤Ç·è¤Þ¤ê¤Þ¤¹¡£
        ¥ê¥ó»é¼Á¤ò¹½À®¤¹¤ë»éËûÀ¤ÎÉÔË°ÏÂÅÙ¡ÊÆó½Å·ë¹ç¤Î¿ô¡Ë¤Ë±Æ¶Á¤µ¤ì¡¢Æó½Å·ë¹ç¤ò»ý¤Äú²½¿åÁǤ¬Â¿¤¤¤Û¤É¡ÊÆó½Å·ë¹ç¤¬¤¢¤ë¤È¤½¤ÎÉôʬ¤Çú²½¿åÁǤ¬ÀÞ¤ì¶Ê¤¬¤ë¤Î¤Ç¡Ë¥ê¥ó»é¼Á¤ÎÁê¸ßºîÍѤ¬Ä㤯¤Ê¤êήưÀ­¤ÏÁý¤¹¤³¤È¤Ë¤Ê¤ê¤Þ¤¹¡£
        DHA¤ÏÉÔË°ÏÂÅÙ¤¬¶Ë¤á¤Æ¹â¤¯ºÙ˦Ëì¤ÎήưÀ­¤ÎÊÝ»ý¤Ë´óÍ¿¤·¤Æ¤¤¤Þ¤¹¡£
        DHA¤ÏÀº±Õ¤äǾ¡¢ÌÖËì¤Î¥ê¥ó»é¼Á¤Ë´Þ¤Þ¤ì¤ë»éËûÀ¤Î¼çÍפÊÀ®Ê¬¤Ç¤¹¡£
        DHA¤ÏǾÆâ¤Ë¤â¤Ã¤È¤âË­É٤˸ºß¤¹¤ëĹº¿ÉÔË°Ï»éËûÀ¤Ç¡¢EPA¤ÏǾÆâ¤Ë¤Û¤È¤ó¤É¸ºß¤·¤Þ¤»¤ó¡£

         

        ¢ã´üÂÔ¤µ¤ì¤ëºîÍÑ¢ä
        1. ¹³±ê¾ÉºîÍÑ
        2. ¹³»À²½
        3. ²òÆǺîÍÑ
        4. ³Ø½¬µ¡Ç½¸þ¾åºîÍѡʵ­²±²þÁ±¡¢·òǾºîÍÑ¡Ë
        5. À©¤¬¤óºîÍÑ¡ÊÆäËÆý¤¬¤ó¡¢ÂçIJ¤¬¤ó¡¢ÇÙ¤¬¤óÅù¡Ë
        6. ÌÖËìÈ¿¼Íǽ¸þ¾åºîÍÑ¡Ê»ëÎÏÄã²¼ÍÞÀ©¡Ë
        7. ¹³·ìÀòºîÍÑ¡Ê·ì¾®ÈĶŽ¸ÍÞÀ©ºîÍÑ¡Ë ¤Ê¤É¡¦¡¦¡¦


        ¡ÚÍÕ»ÀÂå¼Õ¤È¤¦¤ÄÉ¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡ã¥Ó¥¿¥ß¥ó¡ä

        0

          JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

           

          ¡ÚÍÕ»ÀÂå¼Õ¤È¤¦¤ÄÉ¡ۡ¡
          ¤¦¤Äɼ£ÎŤÏÌôʪÎÅË¡¤È¿´ÍýÎÅË¡¤¬Ãæ¿´¤Ç¤¹¤¬¡¤±ÉÍÜÎÅË¡¤È¤·¤Æ¡¤ÍÕ»À¤òÊäÌô¤È¤·¤Æ»ÈÍѤ¹¤ë¼£ÎŤÎÍ­¸úÀ­¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

          ¸½ºß¡¤¿©»ö¤«¤éÀݼè¤Ç¤­¤ë±ÉÍÜÁǤÎÃæ¤ÇݵɤȤδØÏ¢¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤ë¤Î¤Ï¡¤DHA¡¦EPA¡¦α-¥ê¥Î¥ì¥ó»ÀÅù¤Î n-3 ·Ï»éËûÀ¡¤ÍÕ»À¤ò´Þ¤à¥Ó¥¿¥ß¥óB ·²¤Ç¤¹¡£
          ÍÕ»À¤Ï 1-C Âå¼Õ¡¤¤¤¤ï¤æ¤ë¥á¥Á¥ª¥Ë¥ó¤ÎÂå¼Õ·Ï¤Ç¥á¥Á¥ë´ð¤ò¶¡µë¤¹¤ë½ÅÍפʱÉÍÜÁǤǤ¹¡£
          ·Ð¸ýÀݼ褷¤¿¥¢¥ß¥Î»À¤«¤éÀ¸¤¸¤ëÍ­³²¤Ê¥Û¥â¥·¥¹¥Æ¥¤¥ó¤ÎÂå¼Õ¤Ë¤ÏÍÕ»À¡¤¥Ó¥¿¥ß¥ó B2¡¤¥Ó¥¿¥ß¥ó B6¡¤¥Ó¥¿¥ß¥ó B12¤¬ÉԲķç¤Ç¤¢¤ê¡¤¤³¤ì¤é¤Î±ÉÍÜÁǤ¬·ç˳¤¹¤ë¤³¤È¤Ë¤è¤Ã¤ÆÍ­³²¤Ê·ìÃæ¥Û¥â¥·¥¹¥Æ¥¤¥ó¤¬Áý²Ã¤·¤Þ¤¹¡£
          ¤µ¤é¤Ë¡¤¤³¤¦¤·¤¿È¿±þ¤Ë¤Ï¥á¥Á¥ì¥ó¥Æ¥È¥é¥Ò¥É¥íÍÕ»À´Ô¸µ¹ÚÁǡʰʲ¼¡¤MTHFR¡Ë°äÅÁ»Ò¿·¿¤¬±Æ¶Á¤·¤Æ¤ª¤ê¡¤MTHFR TT ·¿¤Ï¤½¤Î¹ÚÁdzèÀ­¤¬Äã²¼¤·¡¤¿©Éʤ«¤é½½Ê¬¤ËÍÕ»À¤òÀݼ褷¤Æ¤¤¤Æ¤â¡¤ÄãÍÕ»À¡¤¹â¥Û¥â¥·¥¹¥Æ¥¤¥ó·ì¾É¤ò¾·¤­¤ä¤¹¤¤¤³¤È¤¬ 300 ¿Í¤ÎÆüËܿͤòʬÀϤ·¤Æ²òÌÀ¤µ¤ì¤Þ¤·¤¿¡£
          Hiraoka M, Kato K, Saito Y, Yasuda K, Kagawa Y¡Ê2004¡ËGene-nutrient and gene-gene interactions of controlled folate intake by Japanese women. Biochem Biophys Res Commun 316: 1210‒6.
          ¤¦¤ÄÉ´µ¼Ô¤ä¹³¤¦¤ÄÌô¤Î¸ú²Ì¤¬½Ð¤Ë¤¯¤¤´µ¼Ô¤ÎÃæ¤Ë¡¤ÍÕ»ÀÀݼèÎ̤¬¾¯¤Ê¤¤¡¤¤Þ¤¿¤Ï·ìÃæÍÕ»ÀÇ»ÅÙ¤¬Ä㤤¼Ô¤¬Â¿¤¤¤³¤È¤¬¿ô¿¤¯Êó¹ð¤µ¤ì¤Æ¤ª¤ê¡¤ºÇ¶á¤ÎÁíÀâ¤Ç¤âÍÕ»À·ç˳¼Ô¤Ïݵ¾É¾õȯ¾É¤Î¥ê¥¹¥¯¤¬¹â¤¤¤³¤È¤¬¼¨º¶¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
          Gilbody S, Lightfoot T, Sheldon T ¡Ê2007¡Ë Is low folate a risk factor for depression? A metaanalysis and exploration of heterogeneity. J Epidemiol Community Health 61 : 631‒7.
          ¤µ¤é¤Ë¡¤¤¦¤Äɤȥۥ⥷¥¹¥Æ¥¤¥ó¤Î´ØÏ¢¤ä¤¦¤ÄɤÈMTHFR TT·¿¤Î´ØÏ¢¤ò¼¨¤¹Êó¹ð¤â¤¢¤ê¤Þ¤¹¡£
          Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM.¡Ê2003¡ËFolate, vitamin B12, homocysteine, and the MTHFR 677C→T polymorphism in anxiety and depression : the Hordaland Homocysteine Study. Arch Gen Psychiatry 60: 618‒26.

          ¡Ú»º¸å¤Ë¡¢¼ê¼ó¤ÎÙŻئ¤Î秾ä±ê¤Ë¤Ê¤Ã¤¿Êý¤¤¤Þ¤¹¤«¡©¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡ãÅ´¡ä

          0

            JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

             

            ¡Ú»º¸å¤Ë¡¢¼ê¼ó¤ÎÙŻئ¤Î秾ä±ê¤Ë¤Ê¤Ã¤¿Êý¡¢¤¤¤Þ¤¹¤«¡©¡Û


            »º¸å¤ÎÅ´·ç˳¤Î½÷À­¤Ç¼ê¼ó¤òÄˤá¤Æ¤¤¤ë½÷À­¡¢»þ¡¹¿Ç¤Þ¤¹¡£

             

            ¡Á¡Ö¥É¥±¥ë¥Ð¥óÉ¡ʶ¹ºõÀ­ç§¾ä±ê¡Ë¡×¡Á

            Êì»Ø¡Ê¿Æ»Ø¡Ë¤ò¹­¤²¤ë¤È¼ê¼ó¡Ê¼ê´ØÀá¡Ë¤ÎÊì»Ø¦¤ÎÉôʬ¤Ë秤¬Ä¥¤Ã¤ÆÈé²¼¤Ë2ËܤÎÀþ¤¬É⤫¤Ó¾å¤¬¤ê¤Þ¤¹¡£¥É¥±¥ë¥Ð¥óɤϤ½¤ÎÊì»Ø¦¤ÎÀþ¤Ç¤¢¤ëûÊì»Ø¿­¶Ú秤ÈĹÊì»Ø³°Å¾¶Ú¤¬¼ê¼ó¤ÎÇئ¤Ë¤¢¤ë¼êÇØÂè°ì¥³¥ó¥Ñ¡¼¥È¥á¥ó¥È¤òÄ̤ë¤È¤³¤í¤ËÀ¸¤¸¤ë秾ä±ê¤Ç¤¹¡£

            ¼ê¼ó¡Ê¼ê´ØÀá¡Ë¤ÎÊì»Ø¦¤Ë¤¢¤ë秾ä¡Ê¼êÇØÂè°ì¥³¥ó¥Ñ¡¼¥È¥á¥ó¥È¡Ë¤È¤½¤³¤òÄ̲᤹¤ë秤˱ê¾É¤¬µ¯¤³¤Ã¤¿¾õÂ֤ǡ¢ç§¾ä¤ÎÉôʬ¤Ç秤ÎÆ°¤­¤¬¥¹¥à¡¼¥º¤Ç¤Ê¤¯¤Ê¤ê¡¢¼ê¼ó¤ÎÊì»Ø¦¤¬Äˤߡ¢¼ð¤ì¤Þ¤¹¡£Êì»Ø¤ò¹­¤²¤¿¤ê¡¢Æ°¤«¤·¤¿¤ê¤¹¤ë¤È¤³¤Î¾ì½ê¤Ë¶¯¤¤áÖÄˤ¬Áö¤ê¤Þ¤¹¡£

            Ãí¡§Ã»Êì»Ø¿­¶Ú秤ϼç¤ÎÊì»Ø¤ÎÂè2´ØÀá¤ò¿­¤Ð¤¹Æ¯¤­¤ò¤¹¤ë秤Î1¤Ä¤Ç¤¹¡£
            ĹÊì»Ø³°Å¾¶Ú秤ϼç¤ËÊì»Ø¤ò¹­¤²¤ëƯ¤­¤ò¤¹¤ë秤Î1¤Ä¤Ç¤¹¡£

             

            ­¡Ã»Êì»Ø¿­¶Ú秡ʤ¿¤ó¤Ü¤·¤·¤ó¤­¤ó¤±¤ó¡Ë
            ¼ç¤ËÊì»Ø¤ò¿­¤Ð¤¹Æ¯¤­¤ò¤¹¤ë秤ΰìËܤǤ¹¡£
            ­¢Ä¹Êì»Ø³°Å¾¶Ú秡ʤÁ¤ç¤¦¤Ü¤·¤¬¤¤¤Æ¤ó¤­¤ó¤±¤ó¡Ë
            ¼ç¤ËÊì»Ø¤ò¹­¤²¤ëƯ¤­¤ò¤¹¤ë秤ΰìËܤǤ¹¡£
            ­£ç§¾ä¡Ê¤±¤ó¤·¤ç¤¦¡Ë

            ­¡¤È­¢¤Î秤¬Ä̤ë¥È¥ó¥Í¥ë¤Ç¤¹¡£

            ¾åµ­¤ÎÉô°Ì¤Ë¼ðı¤ä°µÄˤ¬¤¢¤ê¡¢Êì»Ø¤È°ì½ï¤Ë¼ê¼ó¤ò¾®»Ø¦¤Ë¶Ê¤²¤ë¤ÈÄˤߤ¬¤¤¤Ã¤½¤¦¶¯¤¯¤Ê¤ë¤³¤È¤Ç¿ÇÃǤ·¤Þ¤¹¡Ê¥Õ¥£¥ó¥±¥ë¥·¥å¥¿¥¤¥ó¥Æ¥¹¥ÈÊÑË¡¡Ë¡£

             

             

             

            https://www.joa.or.jp/public/sick/condition/de_quervain_disease.html


            ¡Ú»À²½¥¹¥È¥ì¥¹¡¦±ê¾É¤ÈÀº¿À¼À´µ¡ÛDr.±üÊ¿¡öÀº¿À²Ê°å¤Î¤Ò¤È¤ê¸À

            0

              JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

               

              ¡Ú»À²½¥¹¥È¥ì¥¹¡¦±ê¾É¤ÈÀº¿À¼À´µ¡Û
              Åý¹ç¼ºÄ´¾É¤ÎÉÂÂ֤ˤϰäÅÁŪÍ×°ø¤ä´Ä¶­ÅªÍ×°ø¤¬¿¼¤¯Íí¤ß¹ç¤Ã¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤Æ¤ª¤ê¡¤¿ô¿¤¯¤ÎÉÂÂÖ²¾À⤬Ä󾧤µ¤ì¤Æ¤¤¤Þ¤¹¡£
              ¶áǯ¡¤»À²½Åª¥¹¥È¥ì¥¹¤ä±ê¾É¤¬¡¤Åý¹ç¼ºÄ´¾É¤ÎÉÂÂ֤˿¼¤¯¤«¤«¤ï¤Ã¤Æ¤¤¤ë¤³¤È¤¬È½¤Ã¤Æ¤­¤Þ¤·¤¿¡£
              Do KQ, Conus P and Cuenod M¡Ê2010¡ËRedox dysregulation and oxidative stress in schizophrenia¡§ nutrigenetics as a challenge in psychiatric disease prevention. J Nutrigenet Nutrigenomic, 3¡Ê4¨¡6¡Ë¡§ 267¨¡289
              Î㤨¤Ð¡¤À¸ÂÎÆâ¤Î»À²½Åª¥¹¥È¥ì¥¹¤Ë¤«¤«¤ï¤ë¹³»À²½Êª¼Á¥°¥ë¥¿¥Á¥ª¥ó¤¬¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǾÀÔ¿ñ±ÕÃæ¤ÇÍ­°Õ¤Ë¸º¾¯¤·¤Æ¤¤¤ë¤³¤È¡¤¤Þ¤¿¥×¥í¥È¥óMRS¤òÍѤ¤¤¿¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎÁ°Æ¬Èé¼Á¤Ë¤ª¤±¤ë¥°¥ë¥¿¥Á¥ª¥óÇ»ÅÙ¤¬Í­°Õ¤ËÄã²¼¤·¤Æ¤¤¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¤Þ¤·¤¿¡£
              Do KQ, Trabesinger AH, Kirsten¨¡Kruger M, et al ¡Ê2000¡ËSchizophrenia¡§glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci, 12¡Ê10¡Ë¡§ 3721¨¡3728.
              É®¼Ô¤é¤Ï¡¤Ç¾Æ⥰¥ë¥¿¥Á¥ª¥óÇ»Å٤ȱ¢À­¾É¾õ¤Î½Å¾ÉÅ٤δ֤ËÉé¤ÎÁê´Ø´Ø·¸¤¬¤¢¤ë¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£
              Potvin S, Stip E, Sepehry AA, et al¡Ê2008¡Ë Inflammatory cytokine alterations in schizophrenia¡§ a systematic quantitative review. Biol Psychiatry, 63 ¡Ê8¡Ë¡§ 801¨¡808.
              ¤Þ¤¿¡¤¥°¥ë¥¿¥Á¥ª¥ó¤ÎÁ°¶îÂΤǤ¢¤ëN¨¡acetyl cysteine¡ÊNAC¡Ë¤ÎÅý¹ç¼ºÄ´¾É´µ¼Ô¤Î±¢À­¾É¾õ¤Ë¤ª¤±¤ë¼£ÎŸú²Ì¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
              Berk M, Copolov D, Dean O, et al¡Ê2008¡ËN¨¡acetyl cysteine as a glutathione precursor for schizophrenia ¨¡a double¨¡blind, randomized placebo¨¡controlled trial. Biol Psychiatry, 64¡Ê5¡Ë¡§ 361¨¡368.
              ¤µ¤é¤Ë¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤Î·ì±ÕÃæ¤Î±ê¾ÉÀ­¥µ¥¤¥È¥«¥¤¥óÇ»ÅÙ¤¬¡¤·ò¾ï¼Ô¤ÈÈæ³Ó¤·¤ÆÍ­°Õ¤Ë¹â¤¤¤³¤È¤¬¡¤¥á¥¿²òÀϤ«¤é¤âÊó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
              Potvin S, Stip E, Sepehry AA, et al¡Ê2008¡Ë Inflammatory cytokine alterations in schizophrenia¡§ a systematic quantitative review. Biol Psychiatry, 63 ¡Ê8¡Ë¡§ 801¨¡808.
              ¤Þ¤¿¡¤¡Î11C¡ÏPK111195¡ÊËö¾¿À­¥Ù¥ó¥¾¥¸¥¢¥¼¥Ô¥ó¼õÍÆÂÎÙɹ³Ìô¡Ë¤òÍѤ¤¤¿PET¡Êpositron emission tomography¡Ë¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǾ¤Ç¤Ï¡¤¥ß¥¯¥í¥°¥ê¥¢¤Î³èÀ­²½¤¬µ¯¤­¤Æ¤¤¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£
              Hashimoto K¡Ê2008¡ËMicroglial activation in schizophrenia and minocycline treatment. Prog Neuropsychopharmacol Biol Psychiatry, 32¡Ê7¡Ë¡§ 1758¨¡1759.
              ¢¨¥ß¥¯¥í¥°¥ê¥¢¡§Ç¾¤äÀÔ¿ñ¤Ë¸ºß¤¹¤ëÌȱֺÙ˦¤Ç¡¢Ãæ¿õ¿À·Ð·Ï¤ò¹½À®¤¹¤ëºÙ˦¤ÎÌ󣵡Á£²£°¡ó¤òÀê¤á¤ë¡£Àµ¾ï¾õÂ֤ǤϺÙŤ¤Æ͵¯¤òÆ°¤«¤·¤Ê¤¬¤é¼þ°Ï¤Î´Ä¶­¤ò´Æ»ë¤·¤Æ¤¤¤ë¡£¤·¤«¤·¡¢¿À·ÐºÙ˦¤Î¾ã³²¤Ê¤É¤Ë¤è¤ê¡¢²áÅ٤˳èÀ­²½¤¹¤ë¤È¡¢±ê¾ÉÀ­Êª¼Á¡Ê±ê¾ÉÀ­¥µ¥¤¥È¥«¥¤¥ó¤Ê¤É¡Ë¤ò»ºÀ¸¤·¡¢¿À·ÐºÙ˦¤Îµ¡Ç½°Û¾ï¤Ê¤É¤ò°ú¤­µ¯¤³¤¹¤³¤È¤¬ÃΤé¤ì¤Æ¤¤¤ë¡£
              ºÇ¶á¡¤»×½Õ´ü¤Ë¤ª¤±¤ëNAC¤ÎÅêÍ¿¤¬¡¤¿·À¸»ù¤Î³¤ÇÏÇ˲õ¥â¥Ç¥ë¤ÎÀ®½Ï´ü¤Ë¤ª¤±¤ëÀº¿ÀɤÎȯ¾É¤òͽËɤǤ­¤ë¤³¤È¤ò¼¨¤¹ÏÀʸ¤¬È¯É½¤µ¤ì¤Þ¤·¤¿¡£
              Cabungcal JH, Counotte DS, Lewis EM, et al¡Ê2014¡Ë Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron, 83¡Ê5¡Ë¡§ 1073¨¡1084.
              ¤³¤Î¤è¤¦¤Ë¡¤Á°Î×¾²»î¸³¥â¥Ç¥ë¤Ë¤ª¤¤¤Æ¡¤¹³»À²½Êª¼ÁNAC¤Ï¡¤Åý¹ç¼ºÄ´¾É¤Ê¤É¤ÎÀº¿À¼À´µ¤Îȯ¾É¤òͽËɤǤ­¤ë²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£
              ¥Ï¥¤¥ê¥¹¥¯»ù¤òÍѤ¤¤¿¸¦µæ¤«¤é¡¤Åý¹ç¼ºÄ´¾É¤Ê¤É¤ÎÀº¿Àɤ˰ܹԤ¹¤ë³ä¹ç¤Ï¡¤Ìó30¡óÄøÅ٤Ǥ¢¤ë¤³¤È¤«¤é¡¤Àº¿ÀɤÎͽËɤȤ¤¤¦´ÑÅÀ¤«¤é¤¹¤ë¤È¡¤°ÂÁ´¤Ê²½¹çʪ¤¬Ë¾¤Þ¤ì¤Þ¤¹¡£
              Î㤨¤Ð¡¤Àĵû¤Ë´Þ¤Þ¤ì¤ëω3 »éËûÀ¤Ï¡¤¥Ï¥¤¥ê¥¹¥¯»ù¤ÎÀº¿ÀɤؤΰܹԤòÍ­°Õ¤ËÄã²¼¤µ¤»¤ë¤³¤È¤¬Êó¹ð¤µ¤ì¡¤ÃíÌܤµ¤ì¤Þ¤·¤¿¡£
              Amminger GP, Schäfer MR, Papageorgiou K, et al ¡Ê2010¡ËLong¨¡chain omega¨¡3 fatty acids for indicated prevention of psychotic disorders¡§a randomized, placebo¨¡controlled trial. Arch Gen Psychiatry, 67¡Ê2¡Ë¡§ 146¨¡154.
              ¤³¤Î¤è¤¦¤Ë¡¤¿©»ö¤È¤·¤ÆÀݼè²Äǽ¤Ê²½¹çʪ¤Ë¤è¤ê¡¤Àº¿À¼À´µ¤ÎͽËɤ¬²Äǽ¤Ç¤¢¤ì¤Ð¡¤Àº¿À¼À´µ¤ÎͽËɤȤ¤¤¦´ÑÅÀ¤«¤é¤¹¤ë¤È¡¤Èó¾ï¤Ë½ÅÍפǤ¹¡£
              ºÇ¶á¡¤É®¼Ô¤é¤ÏÅý¹ç¼ºÄ´¾É´µ¼Ô¤òÂоݤȤ·¤¿¥ª¡¼¥×¥ó¸¦µæ¤Ç¡¤sulforaphane´ÞÍ­¤Î¥Ö¥í¥Ã¥³¥ê¡¼Ãê½Ðʪ¤¬¡¤Åý¹ç¼ºÄ´¾É´µ¼Ô¤ÎǧÃε¡Ç½¾ã³²¤ò²þÁ±¤¹¤ë¤³¤È¤ò¸«½Ð¤·¤Þ¤·¤¿¡£
              Shiina A, Kanahara N, Sasaki T, et al¡Ê2015¡ËAn open study of sulforaphane¨¡rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci, In press.
              ¤µ¤é¤Ë¡¤2014 ǯ10 ·î¤ËÊƹñ¤ÎHarvardÂç³Ø¤ÈJohns HopkinsÂç³Ø¤Î¸¦µæ¼Ô¤¬¡¤¼«Êľɥ¹¥Ú¥¯¥È¥é¥à¾ã³²¤òÂоݤȤ·¤¿¥×¥é¥»¥ÜÂоȻ¤Çsulforaphane´ÞÍ­¤Î¥Ö¥í¥Ã¥³¥ê¡¼Ãê½Ðʪ¤¬Í­°Õ¤Ë¼«Êľɾɾõ¤ò²þÁ±¤¹¤ë¤³¤È¤òÊó¹ð¤·¤Þ¤·¤¿¡£
              Singh K, Connors SL, Macklin EA, et al¡Ê2014¡Ë Sulforaphane treatment of autism spectrum disorder ¡ÊASD¡Ë. Proc Natl Acad Sci USA, 111¡Ê43¡Ë¡§ 15550- 15555.
              Japanese Journal of Biological Psychiatry Vol.26, No.1, 2015

              ¡Ú¤Æ¤ó¤«¤ó´µ»ù¤Î¿ç̲¤È¿©»ö¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㤽¤Î¾¡ä

              0

                JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

                 

                ¡Ú¤Æ¤ó¤«¤ó´µ»ù¤Î¿ç̲¤È¿©»ö¡Û

                ¡¡

                ¤Æ¤ó¤«¤ó¤ò´µ¤Ã¤Æ¤¤¤ë¤¿¤á¤Ëº¹Ê̤ò¼õ¤±¤ë¤³¤È¤Ê¤¯¡¢²ÈÄíÀ¸³è¤Ë¤ª¤±¤ë¼Á¡Ê£Ñ£Ï£Ì¡Ë¤Î¸þ¾å¤òÌܻؤ·¤Þ¤¹¡£

                 

                 ¿ç̲»þ´Ö

                ¿ç̲ÉÔ­¤¬È¯ºî¤òͶȯ¤·¤ä¤¹¤¤¤³¤È¤Ï¡¢°ìÈÌŪ¤ËÃΤé¤ì¤Æ¤¤¤Þ¤¹¡£´µ»ù¤ÎǯÎð¤Ë¤è¤Ã¤ÆɬÍפʻþ´Ö¤ÏÍÍ¡¹¤Ç¤¹¤¬¡¢À®Ä¹´ü¤Ç¤¢¤ëÅÀ¤ò¹Íθ¤¹¤ë¤È¡¢£¸»þ´Ö°Ê¾å¤òÌÜɸ¤È¤¹¤ë¡£ ³ÐÀä·¤¿¤È¤­¤Ë̲¤¯¤Ê¤¤¤³¤È¤äÃ뿲¤ò¤·¤Ê¤¤ÄøÅÙ¤òÌܰ¤Ȥ¹¤ë¤È¡¢³Æ´µ»ù¤Ë¤¢¤Ã¤¿¿ç̲»þ´Ö¤òÀßÄê¤Ç¤­¤ë¡£¼õ¸³´ü¤Î´µ»ù¤ÏÆñ¤·¤¤¤¬¡¢ºÇû¤Ç¤â£¶»þ´Ö°Ê¾å¤ÏÆþ̲¤¹¤ë¤³¤È¤òµÁ̳ÉÕ¤±¤Æ¡¢ÉÔ­¤òÊ䤦¤¿¤á¤ÎÃ뿲¤Ï²Ä¡£

                 

                ¿©»ö

                ³Æ¹³¤Æ¤ó¤«¤óÌô¤Ë¤è¤ê¡¢Áê¸ßºîÍѤÏÍÍ¡¹¤Ç¤¢¤ë¡£ ¿©»ö¤ÎÃæ¤ÇÃí°Õ¤¹¤ë¤â¤Î¤Ï¥°¥ì¡¼¥×¥Õ¥ë¡¼¥Ä¡££Ã£Ù£Ð£³£Á£´¤¬Î§Â®¹ÚÁǤǤ¢¤ë£Ã£Â£Ú¡Ê¥«¥ë¥Þ¥Þ¥¼¥Ô¥ó¡Ë¤ä £Ú£Î£Ó¡Ê¥¾¥Ë¥µ¥ß¥É¡Ë¤Î¾ì¹ç¤Ë¡¢·ìÃæÇ»ÅÙ¤¬¾å¾º¤¹¤ë¶²¤ì¤¬¤¢¤ë¡£²Ì¼Â¡¢¥¸¥å¡¼¥¹¤È¤â¤Ë¡¢ÆâÉþ´ü´ÖÃæ¤Ë¤Ï¹µ¤¨¤ë¡£

                ¢¨CYP3A4¡§¥·¥È¥¯¥í¥àP450 3A4 (CYP3A4) ¤Ï¥·¥È¥¯¥í¥àP450 (CYP) ¤Îʬ»Ò¼ï¤Î°ì¼ï.

                ¿ÍÂΤ˸ºß¤¹¤ëÀ¸ÂΰÛʪ (xenobiotic) ¤òÂå¼Õ¤¹¤ë¹ÚÁǤμçÍפʤâ¤Î¤Î1¤Ä¤Ç¤¢¤ë¡£¼ç¤Ë´Î¡¤Ë¸ºß¤¹¤ë¤¬¡¢Âå¼Õ¤Ë½ÅÍפÊÌò³ä¤ò²Ì¤¿¤¹Â¾¤Î´ï´±¤äÁÈ¿¥Ãæ¤Ë¤â¤ß¤é¤ì¤ë¡£¾®Ä²¤Ë¤âË­ÉÙ¤Ëȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤¬ÃΤé¤ì¤Æ¤ª¤ê¡¢Æä˷иýÅêÍ¿¤·¤¿Ìôʪ¤Î½é²óÄ̲á¡Ê·Ð¸ýÅêÍ¿¤µ¤ì¤¿Ìôʪ¤¬½Û´Ä·Ï¤ËÆþ¤ë¤Þ¤Ç¤Ë¾Ã²½´É¡¢´Î¡¤ÇÂå¼Õ¤ò¼õ¤±¡¢Âν۴Ĥ˽и½¤¹¤ëÌôʪÎ̤¬¾¯¤Ê¤¯¤Ê¤ë¸ú²Ì¡Ë¤Ë¤ª¤±¤ëÂå¼Õ¤Ë½ÅÍפÊÌò³ä¤ò²Ì¤¿¤·¤Æ¤¤¤Þ¤¹¡£

                ¤¢¤ë¼ï¤ÎÌôºÞ¤ÎÂå¼Õ¤Ë¤âÂ礭¤¯´Ø¤ï¤Ã¤Æ¤¤¤ë¡£

                ¥°¥ì¡¼¥×¥Õ¥ë¡¼¥Ä¥¸¥å¡¼¥¹Ãæ¤Îʪ¼Á¤¬ CYP3A4 ¤òÁ˳²¤·¡¢Âå¼Õ¤òÃ٤餻¤ë¤³¤È¤Ë¤è¤ê·ìÃæÇ»ÅÙ¤ò¾å¾º¤µ¤»¤Þ¤¹¡£¤½¤Î¤¿¤á¡¢ÌôʪÂå¼Õ¹ÚÁǤǤ¢¤ë¥Á¥È¥¯¥í¡¼¥à P450 3A4¡ÊCYP3A4¡Ë¤Ë¤è¤êÂå¼Õ¤µ¤ì¤ë¤³¤È¤¬ÃΤé¤ì¤Æ¤¤¤ëÌôºÞ¤È¥°¥ì¡¼¥×¥Õ¥ë¡¼¥Ä¥¸¥å¡¼¥¹¤È°ì½ï¤ËÉþÍѤ¹¤ë¤È¡¢·ìÃæÇ»ÅÙ¤¬¾å¾º¤·ÌôºÞ¤ÎºîÍѤ¬¶¯¤¯¤¢¤é¤ï¤ì¡¢ÉûºîÍѤ¬È¯¸½¤¹¤ë²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£

                 

                ¿Þ¡§http://kusuri-jouhou.com/pharmacokinetics/taisha.html

                 

                ½Ðŵ¡§CLINICIAN  17  NO. 657¡¡89(511)98¡Ê520¡Ë

                http://medical.eisai.jp/clinician/vol64/no657/pdf/sp13_657.pdf¡¡

                 

                 


                ¡ÚDr.±üÊ¿¤Î±ÉÍܲòÀϹֺ¡ۿ©»ö±ÉÍÜÎÅË¡俱³ÚÉô2017inÀ¹²¬¡§±üÊ¿ÃÒÇ·ÀèÀ¸

                0

                  JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

                   

                  ¡Ú¿©»ö±ÉÍÜÎÅË¡¶æ³ÚÉô2017inÀ¹²¬¡Û
                  ¡ÁDr.±üÊ¿¤Î±ÉÍܲòÀϹֺ¡Á
                  Æü»þ¡§2017ǯ6·î28Æü¡Ê¿å¡Ë¡¡12:30¡Á14:30

                  ¡û±üÊ¿ÃÒÇ·¡Ê¤ª¤¯¤À¤¤¤é¡¡¤È¤â¤æ¤­¡ËÀèÀ¸
                  °åÎÅË¡¿Í»³¸ýɱ¡¡¡Àº¿À²ÊÉôĹ
                  Åìµþ½÷»Ò°å²ÊÂç³ØÅìÍΰå³Ø¸¦µæ½ê
                  ¿·½É¹Â¸ý¥¯¥ê¥Ë¥Ã¥¯
                  ºë¶Ì¥á¥ó¥¿¥ë¥Ø¥ë¥¹¸òή²ñ SMN¡¡²ñĹ
                  https://www.kamponavi.com/doctor/d65mizoguchi.html

                  ¡ùDr.±üÊ¿ ¥×¥í¥Õ¥£¡¼¥ë¡ù×Ä 

                  https://www.kamponavi.com/m/doctor/d13yama.html

                  ¡úDr.±üÊ¿ ¹ÖºÂ°ÆÆâ¡ú 

                  http://mhealth.jugem.jp/
                  ¡ùTwitter/¿©»ö±ÉÍÜÎÅË¡¶æ³ÚÉô Dr.±üÊ¿¡ù 

                  https://twitter.com/syokujieiyo

                   ¡ú¥Ç¡¼¥¿¤Î²ò¼á´õ˾¼Ô¤Ï·ì±Õ¸¡ºº·ë²Ì¤ò¤ª»ý¤Á¤¯¤À¤µ¤¤
                  ¡¦»²²Ã¾ò·ï¡§¤É¤Ê¤¿¤Ç¤â¤´»²²Ã¤¤¤¿¤À¤±¤Þ¤¹
                  ¡¦²ñ¾ì¡§¥Û¥Æ¥ë¥á¥È¥í¥Ý¥ê¥¿¥óÀ¹²¬¡¡¥Á¥ã¥¤¥Ë¡¼¥º¥À¥¤¥Ë¥ó¥°¡ÖJUEN¡×¡¡¡¡
                  TEL¡§019-629-2612¡¡¡¡¡¡À¹²¬±Øľ·ë¡¡http://testmorioka.metropolitan.jp/restaurant_list/¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡
                  ¡¦»²²ÃÈñ¡§ ̵ÎÁ
                  ¡¦¤´°û¿©Âå¤Ï³Æ¼«Àº»»¡Ê2,000±ß¤Î¥é¥ó¥Á¥³¡¼¥¹+¤ª°û¤ßʪÂå¡Ë
                  ¡¦¥­¥ã¥ó¥»¥ë¡§6/23(¶â)¤Þ¤Ç
                  ¡¦¿½¹þ¤ß¡§ÀèÃå½ç¡ÊÄê°÷¤Ë¤Ê¤ê¼¡ÂèÄù¤áÀÚ¤ê¡Ë
                  ¡¡ ·ï̾¡§6/28ºÂÃ̲ñÂè°ìÉô¿©»ö±ÉÍÜÎÅË¡¶æ³ÚÉô2017inÀ¹²¬
                  ¡¡ ½ê°¡¦Ìò¿¦¡¦»ñ³Ê¡¦½»½ê¡¦ÅöÆü¤ÎÏ¢ÍíÀ衦Facebook¤Î̵ͭ¡¦»²²ÃÍýͳ¤òź¤¨¤Æ
                  ¡¡ syokujieiyo@gmail.com ¡¡¤Þ¤Ç¡¡¤´Ï¢Íí¤¯¤À¤µ¤¤
                  »ö̳¶É¡§Ã滳

                   

                   


                  ¡Ú·Ð·ìÎ̤ÈÅ´ÉÔ­¡ÛDr±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡ãÅ´¡ä

                  0

                    JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

                     

                    ¡Ú·Ð·ìÎ̤ÈÅ´ÉÔ­¡Û

                     

                    Àµ¾ïÈϰϤÏ20¡Á120 mL¤ÇÊ¿¶Ñ60 mL¡¤·ì±Õ°Ê³°¤ÎÀ®Ê¬¤â´Þ¤á¤ÆÊ¿¶Ñ60 g¤Ç¤¹¡£¢ã¸ÄÂκ¹¡¢Âç¢ä

                    À¸Íý¤Ë¤è¤ê¼º¤¦·ì±ÕÎÌ 60mL(Å´30­Ó) /·î

                    ÊØÇ¢´À¤Ç¼º¤¦Å´ÁÓ¼ºÎÌ    30­Ó /·î

                    ·Ð·ìÎ̤Ï50¡Á150g¤¬Àµ¾ï¤ÎÈϰϤǤ¹¤¬¡¢

                    ¤½¤ì°Ê¾å¤Ë½Ð·ìÎ̤¬Â¿¤¯¤Ê¤ë¸½¾Ý¤ò¡¢¡Ö²á¿·î·Ð¡×¤È¸À¤¤¤Þ¤¹¡£

                     

                    ¡Ú²á¿·î·Ð¤Î¸¶°ø¡Û

                    ­¡»ÒµÜÆâË줬¸ü¤¯¤Ê¤ê·Ð·ìÎ̤¬Â¿¤¤

                    ➡»ÒµÜÂΤ¬¤ó¡¢»ÒµÜÆâËìÁý¿£¾É

                    ­¢»ÒµÜ¤Î»ß·ìÎϤ¬¼å¤¤

                    ➡»ÒµÜÆâËì¥Ý¥ê¡¼¥×¡¢»ÒµÜ¶Ú¼ð¡¢ÆÃȯÀ­

                    http://www.shinjuku-clinic.jp/seminar/okudaira

                     

                     


                    ¡ÚÀÝ¿©¾ã³²¤ÈBDNF¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㤽¤Î¾¡ä

                    0

                      JUGEM¥Æ¡¼¥Þ¡§¿©»ö¡¦±ÉÍÜÎÅË¡

                       

                      ¡ÚÀÝ¿©¾ã³²¤ÈBDNF¡Û


                      ǾͳÍè¿À·Ð±ÉÍÜ°ø»Ò¡ÊBrain-derived neurotro-phic factor : BDNF¡Ë¤Ï¡¤É¸ÅªºÙ˦ɽÌ̾å¤Ë¤¢¤ëÆðÛŪ¼õÍÆÂÎ TrkB ¤Ë·ë¹ç¤·¡¤¿À·ÐºÙ˦¤ÎÀ¸Â¸¡¦À®Ä¹¡¦¥·¥Ê¥×¥¹¤Îµ¡Ç½Ð¶¿Ê¤Ê¤É¤Î¿À·ÐºÙ˦¤ÎÀ®Ä¹¤òÄ´À᤹¤ëÃÁÇò¼Á¤Ç¤¹¡£

                      BDNF ¤Ï¡¤¿À·Ð·Ï¤ÎÀ®Ä¹¤äʬ²½¡¤°Ý»ý¡¤Áý¶¯ºîÍѤΤߤʤ餺¡¤¥É¥Ñ¥ß¥ó·Ï¤Ê¤É¤Î¿À·ÐÅÁãʪ¼Á¤ÎÄ´ÀáºîÍÑ¡¤Ä¹´üÁý¶¯¤ä³Ø½¬µ­²±¤Ê¤É¤Î¿À·Ð²ÄÁºÀ­¤ä·ë¹ç¤Îµ¡¹½¤Ë´ØÍ¿¤·¤Æ¤¤¤Þ¤¹¡£

                      ´ðÁø¦µæ¤Ë¤ª¤¤¤Æ¡¤BDNF¥Î¥Ã¥¯¥¢¥¦¥È¥Þ¥¦¥¹¤Î¥¹¥È¥ì¥¹¤ËÂФ¹¤ëÉ԰¡¤³èÆ°À­¤Îж¿Ê¡¤¿©Íßж¿Ê¤¬Êó¹ð¤µ¤ì¤Þ¤·¤¿¡£

                      Rios M, Fan G, Fekete C, et al¡Ê2001¡ËConditional deletion of brain¡Ýderived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol, 15 : 1748¡Ý1757

                       

                      ÀÝ¿©¾ã³²¡ÊEating Disorders : ED¡Ë¤Ï¡¤¼«¸Êɾ²Á¤ËÂФ¹¤ëÂνŤäÂη¿¤Î²á¾ê¤Ê±Æ¶Á¤òÇطʤȤ·¤¿¡¤¿©¹ÔÆ°°Û¾ï¤òÄ褹¤ë¾ã³²¤Ç¤¹¡£
                      ¼ç¤ËÄãÂνš¤ÈîËþ¶²ÉÝ¡¤¤ä¤»´ê˾¡¤¿ÈÂÎÁü¤Î¾ã³²¤äµñ¿©¤òÆÃħ¤È¤·¤¿¡¤¿À·ÐÀ­Ìµ¿©Í߾ɡÊAnorexia Nervosa ¡§ AN¡Ë¡¤²á¿©¤äÇӽйÔÆ°¤òÆÃħ¤È¤·¤¿¿À·ÐÀ­Âç¿©¾É¡ÊBulimiaNervosa ¡§ BN¡Ë¤Ëʬ¤±¤é¤ì¤Þ¤¹¡£

                      ¼ã¤¤½÷À­¤Ë¿¤¯¡¤Á°»×½Õ´ü¤«¤éÀ®¿Í¡¤´ûº§½÷À­¤Þ¤ÇÉý¹­¤¯¸«¤é¤ì¡¤Í­ÉÂΨ¤Ï¡¤AN¤Ï²¤Êƽô¹ñ¤Ç¤Ï¼ã¤¤½÷À­¤Î 0.1 ¡ó¡Á 0.5 ¡ó¡¤BN¤Ï¡¤1.5 ¡ó¡Á 3.8 ¡ó¤È¸À¤ï¤ì¤Æ¤¤¤Þ¤¹¡£

                      Lucas AR, Beard CM, O'Fallon WM, et al¡Ê1991¡Ë50-year trends in the incidence of anorexia nervosa in Rochester, Minn. : a population¡Ýbased study. Am J Psychiatry, 148¡Ê7¡Ë: 917¡Ý922.
                      Garfinkel PE, Lin E, Goering P, et al¡Ê1995¡ËBulimia Nervosa in a Canadian community sample: prevalence and comparison of subgroups. Am J Psychiatry, 152¡Ê7¡Ë: 1052¡Ý1058.

                       

                      ¶áǯ¡¤BDNF ¤È¡¤ED ¤ÎÉÂÂÖÀ¸Íý¤È¤Î´ØÍ¿¤Ë´Ø¤¹¤ë°ìÏ¢¤ÎÃ諤¬Êó¹ð¤µ¤ì¤Æ¤¤¤Þ¤¹¡£

                      BDNF ¤È ED ¤Ë´Ø¤¹¤ë°äÅÁ»Ò¸¦µæ 14¡¤32¡Ë¡¤BDNF °äÅÁ»Ò¤Ë´Ø¤¹¤ë¥á¥¿²òÀϤǤϡ¤BDNF Val/Met¡¤BDNF Met/Met °äÅÁ»Ò¿·¿¤Ç¤Ï¡¤ED ¤Îȯ¾ÉΨ¤¬ 30 ¡óÁý²Ã¤· 32¡Ë¡¤BDNFVal66Met °äÅÁ»Ò¿·¿¡Êrs6265¡Ë¤È ED ¤Î´ØÏ¢¤¬¼¨º¶¤µ¤ì¤Þ¤·¤¿¡£

                      Gratac M, González JR, Mercader JM, et al¡Ê2007¡ËBrain¡Ýderived neurotrophic factor Val66 Met and psychiatric disorders : meta¡Ýanalysis of case¡Ýcontrol studies confirm association to substance¡Ýrelated disorders, eating disorders, and schizophrenia. Biol Psychiatry, 61¡Ê7¡Ë: 911¡Ý922.
                      Mercader JM, Ribasés M, Gratacòs M, et al¡Ê2007¡ËAltered brain¡Ýderived neurotrophic factor blood levels and gene variability are associated with anorexia and bulimia. Genes Brain Behav, 6¡Ê8¡Ë:706¡Ý716.

                       

                      ÆüËܿͤΥµ¥ó¥×¥ë¤òÂÐ¾Ý¤Ë BDNFVal66Met ¤È AN À©¸Â·¿¡¤BN Çӽз¿¤È¤Î´ØÏ¢¤ò¸«½Ð¤·¤Þ¤·¤¿¡£
                      ¤Þ¤¿¡¤·ìÀ¶ BDNF Ãͤ¬¡¤·ò¾ïÂоȼԡÊNC¡Ë¤ËÈæ³Ó¤·¤ÆÍ­°Õ¤Ë¸º¾¯¤·¤Æ¤ª¤ê¡¤ÀÝ¿©¾ã³²¤ÎÍ­ÍѤÊÀ¸Êª³ØŪ¿ÇÃÇ»Øɸ¤Ç¤¢¤ë²ÄǽÀ­¤¬¤¢¤ê¤Þ¤¹¡£

                      Nakazato M, Hashimoto K, Shimizu E, et al¡Ê2003¡ËDecreased levels of serum brain¡Ýderived neurotrophic factor in female patients with eating disorders. Biol Psychiatry, 54¡Ê4¡Ë: 485¡Ý490.

                      Japanese Journal of Biological Psychiatry Vol.21, No.4, 2010

                       


                      | 1/5PAGES | >>

                      calendar

                      S M T W T F S
                          123
                      45678910
                      11121314151617
                      18192021222324
                      252627282930 
                      << June 2017 >>

                      selected entries

                      categories

                      archives

                      recent comment

                      • ¡ÚÌ£Á¹½Á¡Û¥ß¥Í¥é¥ëÊäµë¤Ï¡Ö¤À¤·Ê´¡×¤Ç:¥Þ¥°¥Í¥·¥¦¥à¡¢¥«¥ë¥·¥¦¥à¡¢Å´¡¢°¡±ô¤Ê¤É¡¦¡¦¡¦±üÊ¿¼°¥¹¡¼¥×
                        ¢Í ¤È¤ó½Á (02/06)
                      • ¡ÚÄã¥Þ¥°¥Í¥·¥¦¥à·ì¾É¡§¤É¤ó¤Ê¾É¾õ¡©¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡㰡±ô¡¦¥Þ¥°¥Í¥·¥¦¥à¡ä
                        ¢Í ¼°æµ×¾¼ (05/25)
                      • ¡Ú¶âÂô¡Û±üÊ¿ÃÒÇ·ÀèÀ¸ ±ÉÍֵܹÁ ¥³¥³¥í¤È¥«¥é¥À¤Î·ò¹¯¤Ï¿©»ö¤«¤é 2019.4.20
                        ¢Í üⶶ¤Ê¤ª¤ß (07/13)
                      • ¡ÚBRAIN FOOD¡ÝÅ´¤ÈÀ®ÀÓ¡¦Ç§Ãε¡Ç½¡ÛDr.±üÊ¿¤Î±ÉÍÜ´ÁÊý¼£ÎŹֺ¡ãÅ´¡ä
                        ¢Í À¥ÀîΤ¹á (12/19)

                      links

                      profile

                      search this site.

                      others

                      mobile

                      qrcode

                      powered

                      ̵ÎÁ¥Ö¥í¥°ºîÀ®¥µ¡¼¥Ó¥¹ JUGEM